The 92% ORR data in pancreatic cancer is the primary catalyst — watch for ESMO presentation in October and Phase 3 design announcement in 2H 2026. The $1.0B cash runway removes near-term dilution risk. Monitor for any regulatory feedback on the registrational path and lung cancer monotherapy data later this year.
Price Chart
Executive Summary
Tango Therapeutics reported Q2 2026 net loss of $0.37 per share, slightly wider than the $0.35 loss in Q2 2025, with zero collaboration revenue as the Gilead deal concluded. The key catalyst is the 92% objective response rate for vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer, driving plans for a Phase 3 trial and a $1.0B cash runway through commercialization. The stock's move hinges on the ESMO data presentation and Phase 3 design finalization in 2H 2026, not the financial results themselves.
Key Financial Metrics
Key Facts
- Net loss of $55.3M ($0.37/share) for Q2 2026 vs $38.9M ($0.35/share) in Q2 2025
- Cash position of $1.0B as of June 30, 2026, expected to fund current operating plan
- Vopimetostat + daraxonrasib achieved 92% objective response rate and 90% six-month PFS in MTAP-deleted, RAS-mutant pancreatic cancer
- Company initiating dialogue with regulators for registrational path; Phase 3 trial design to be finalized in 2H 2026
- Phase 1/2 data to be presented at ESMO Congress October 23-27, 2026
- Appointed Fatma Ocak as Chief Commercialization Officer and Robert Azelby as Chairman of the Board
- Research and development expenses increased to $37.2M from $32.8M year-over-year
- General and administrative expenses doubled to $22.6M from $11.3M year-over-year
Financial Impact
Net loss widened by $16.4M year-over-year to $55.3M; cash burn rate approximately $50M per quarter; $1.0B cash runway provides ~5 years of funding at current burn
Risk Factors
- Clinical trial failure in Phase 3 or regulatory setback
- Dependence on Revolution Medicines' RAS(ON) inhibitors for combination therapy
- Widening losses and increasing G&A expenses without near-term revenue
- Competition from other PRMT5 inhibitors and RAS-targeting therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342532 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $25.58 $25.20 | ▲ +1.49% | ▲ +1.04% | $23.33 (+8.78%) |
Aug 11, 2026 7w ago | 8-K | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.33 (−11.41%) |
Aug 11, 2026 7w ago | Press Release | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.33 (−11.41%) |
Aug 9, 2026 7w ago | Institutional Cluster | $27.67 $25.29 | ▼ −8.60% | ▼ −8.55% | $23.33 (−15.67%) |
Aug 6, 2026 8w ago | 8-K | $27.07 $25.60 | ▼ −5.43% | ▼ −5.83% | $23.33 (−13.80%) |
Jun 11, 2026 16w ago | 144 | $30.94 $27.97 | ▼ −9.60% | ▼ −10.27% | $23.33 (−24.58%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.33 (−21.75%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.33 (−21.75%) |
Jun 10, 2026 16w ago | 424B5 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.33 (−21.75%) |
Jun 10, 2026 16w ago | 144 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.33 (−21.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access